Journal of Pharmaceutical Research and Integrated Medical Sciences (JPRIMS)
ISSN: 3049-1681, Vol. 02, Issue No. 03, 2025 (pp. 34-46)

AKT PUBLICATION

REVIEW ARTICLE https://aktpublication.com/index.php/jprims/index

Exploring The Role of Artificial Intelligence in Early Diagnosis of Diabetes

Vaminee Madhukar*[1], and Deepak Kumar Biswas[2]

[1]University Institute of Pharmacy, Pt. Ravishankar Shukla University, Raipur (CG)

[2]Faculty of Pharmaceutical Campus, Shri Shankaracharya Technical Campus, Bhilai (C.G.)

Corresponding Author E-mail: vaminee.madhukar@gmail.com

Abstract

Increasing accuracy and efficiency together with diagnosis predictability makes artificial intelligence (AI) revolutionize healthcare sector operations. This paper explores how artificial intelligence (AI) detects early-stage diabetes mellitus as a metabolic chronic disease that shows increasing global prevalence. The objective of this research study evaluates how different artificial intelligence approaches including machine learning, deep learning, and natural language processing (NLP) function in terms of methods, accuracy level as well as data collection protocols and their practical clinical benefits. Research indicates that ensemble machine learning models alongside convolutional neural networks (CNNs) demonstrate superior identification abilities for detecting diabetes problems early on. The data quality issues along with generalization problems and limitations for clinical practice require further investigation.

Key Words:

Artificial Intelligence (AI), Diabetes Mellitus, Early Detection, Machine Learning (ML), Deep Learning (DL), Natural Language Processing (NLP), Convolutional Neural Networks (CNNs), Predictive Modeling, Clinical Implementation, Data Quality.

History:

Received Jan 22,2025

Accepted Feb 19,2025

Published March 30 ,2025

1. INTRODUCTION

Medical science classifies diabetes mellitus as a lifelong metabolic condition which causes increased blood sugar levels as a major international public health concern [1]. The avoidance of severe complications such as cardiovascular disease and neuropathy and renal failure needs an immediate diagnosis approach [2]. Multiple problems exist with traditional diagnosis techniques because they perform tests occasionally while failing to detect diabetes in its early preclinical period [3].

Figure 1: Diabetes Mellitus

Artificial Intelligence (AI) revolutionized healthcare services during the recent decades by delivering top-level solutions that enhance diagnostic precision together with operational effectiveness and access to healthcare [4]. Artificial Intelligence machines supported by ML and DL and NLP technology can identify early diabetes indicators by processing diverse healthcare information found in EHRs combined with wearable device information and medical images. AI-based models show superior prediction accuracy while they successfully detect patterns which standard approaches fail to notice [5].

1.1.The Emerging Role of AI in Healthcare

Healthcare experiences a transformation through Artificial Intelligence (AI) which allows the development of diagnostic solutions that deliver prompt accurate patient care [6]. Diagnosing diabetes mellitus promptly remains essential for the prevention of complications while improving patient results since this metabolic disorder of extended duration leads to elevated blood sugar levels [7]. Standard diagnostic tests require time-consuming manual evaluation along with resource availability that limits their accessibility mostly to people in under-resourced areas.

Figure 2: Artificial Intelligence (AI) Transforming InHealthcare

A revolutionary approach provided by AI depends on sophisticated computing methods including machine learning (ML) deep learning (DL) and natural language processing (NLP) [8]. Advanced analytical tools evaluate extensive complex data sources consisting of electronic health records (EHRs) and genetic information and medical images to identify diabetical warning indicators very accurately [9]. The review explores how AI approaches reshape the detection of diabetes at early stages and examines their practical medical applications and implementation barriers inside medical infrastructure.

1.2. Background Of the Study

The International Diabetes Federation (IDF) reports that diabetes worldwide continues toward emergency levels of prevalence [10]. In 2021 the worldwide prevalence reached 537 million adults aged 20-79 years among a total adult population of 10%. The current trajectory suggests an increase to 643 million by 2030 and 783 million by 2045 will be the total population with diabetes [11]. Many diabetes patients do not receive their diagnosis until many years pass leading to elevated complication risks that degrade their treatment outcomes [12].

Diabetes management proves most effective through early detection because it promotes better glycemic control while reducing complications risk and improving the general health condition of patients [13]. The standard diagnostic methods involving fasting plasma glucose (FPG) along with oral glucose tolerance tests (OGTT) and glycated haemoglobin (HbA1c) tests are successful but unable to identify people at risk of preclinical diabetes development [14]. The inability to identify preclinical diabetes cases early has pushed healthcare organizations to explore best data-driven solutions which use artificial intelligence as their primary diagnostic tool [15].

The technological evolution of Artificial Intelligence along with machine learning and deep learning has transformed medical practice into an essential revolutionary medical tool [16]. The combination of data processing capability and pattern recognition and predictive analysis functions through AI transformed diabetes diagnosis and management at a critical level [17]. Healthcare professionals who use AI in their diagnostic tasks can identify persons at high risk at earlier stages to initiate personalized preventive measures.

1.3. Objectives of the Study

- To briefly summarize recent AI methods used in diabetes prediction.
- To examine the performance metrics of AI models.
- To address their clinical implications and limitations.

1.4.Importance of the Topic

The rising diabetes incidence stands as a major international health threat due to delayed diabetes detection which generates additional health problems and increased strain on patients and healthcare organizations and their families [18]. The evidence reveals that approximately half of all diabetes cases stay unidentified mainly because low and middle-income countries lack appropriate diagnostic equipment. A revolutionary healthcare development emerges through early diagnosis facilitated by Artificial Intelligence (AI) because AI-based models can process extensive complex data obtained from electronic health records (EHRs), wearable technology and genomic information [19]. By identifying concealed relationships in the data these models detect diabetes or prediabetes cases before symptom development in individuals. AI presents strong potential to enhance medical diagnoses by decreasing human mistakes along with structural differences and by conducting automatic medical data analysis to reduce clinical interpretation duration and create personalized treatment through risk factor predictions from lifestyle components and genomic data and medical records history [20]. Healthcare resources reach their highest efficiency with AI because the technology enables experts to administer screened tests to vulnerable patient groups for optimized preventive care [21]. Through the deployment of telemedicine and specifically designed diagnostic devices patients in remote locations will gain access to diagnostic services because of AI technologies which works towards decreasing healthcare disparities [22]. Four main obstacles that restrain AI use in diabetes diagnosis exist: ethical dilemmas, data protection issues and the need for extensive clinical verification procedures. Research investigates the leading position of AI in diabetes pandemic control by showcasing how AI tools will shift medical practices from reactive to preventative actions which decrease diabetes-linked disabilities and death rates alongside lower financial expenses from diabetes yet improve medical system equity and operational effectiveness [23].

2. AI TECHNIQUES AND THEIR APPLICATIONS IN EARLY DIABETES DIAGNOSIS

2.1. Overview of AI Techniques in Diabetes Diagnosis

The diagnosis of diabetes at an early stage proves highly effective through Artificial Intelligence (AI) methods which analyze complex and varied data collections [24]. The analysis of patient data consisting of insulin levels, genetic factors, BMI, glucose levels and age uses different methods including decision trees and SVM and RF and ANN and deep learning models to identify early diabetes characteristics [25]. Decision trees enable easy interpretation but SVMs excel at small data analysis to differentiate between diabetic and non-diabetic patients. Random Forest achieves high performance through multiple decision tree averaging and missing value management and its capability to prevent overfitting issues [26]. Reputable because of identification capabilities for intricate patterns in structured and unstructured data networks (anns) includes deep learning architectures like CNNs and RNNs for medical image analysis and continuous glucose monitoring detection [27]. The implementation of these methods produces accurate diagnoses in shorter times however ongoing work is essential because data quality combined with generalizability and model interpretation still present challenges.

2.2. Methodologies

Table 1: Key Findings

AI Technique	Dataset	Accuracy (%)	Key Insights
SVM, RF	Pima Indian Diabetes Dataset	79–83	AI outperforms traditional statistical methods.
Decision Tree, Naïve Bayes	PIMA	76–82	Decision Tree models are interpretable and accurate.
CNN	Custom hospital dataset	85–91	CNNs offer strong feature extraction for medical images.

Artificial Intelligence methods demonstrate positive results for diabetes early detection when they operate on various datasets [28]. When applied to Pima Indian Diabetes Dataset through support vector machines and random forest models achieved accuracy that exceeded conventional statistical methods by reaching 79 to 83 percent. The accuracy scores of Decision Tree and Naïve Bayes models matched in the same testing environment reached between 76% and 82%. Medical applications value these models due to their interpretability and usability features which make them ideal for transparent decision-making scenarios [29]. CNNs applying in-house clinical data achieve higher accuracy levels from 85% to 91% when processing medical image data that includes retinal scans with diagnostic imaging. AI diagnostic enhancement techniques show versatility and success in improving accuracy levels thus creating vast opportunities in diabetes detection and management revolution.

2.3 Critical Evaluation

The use of Artificial Intelligence (AI) models for diabetes diagnosis depends on specific contextual requirements because each model demonstrates different monitoring capabilities and operational boundaries [30]. Random Forest models excel at both accuracy and missing data processing thus becoming a powerful method for real-life incomplete datasets.

Table 2: Comparison of Machine Learning Models: Strengths and Weaknesses

Model	Strengths	Weaknesses
Random Forest	High accuracy, handles missing data	Requires tuning, not interpretable
SVM	Effective in small datasets	Poor performance on large datasets
Neural Networks	High adaptability, deep pattern recognition	Black-box nature, computationally intensive

The extensive hyperparameter tuning requirement along with non-interpretable decision-making makes such models unsuitable for clinical transparency requirements. Support Vector Machines (SVM) create successful classifications and distinct boundaries in cases involving small datasets. The difficulty of increasing data volumes leads to degraded performance for these models and thereby reduces their practicality in big data applications [31]. Neural networks exhibit top-notch adaptability and succeed best at uncovering advanced patterns within extensive datasets. The structure of Rephrase Vector Machines enables them to identify complex medical data patterns with their non-linear nature. These systems have major limitations due to being "black-box" systems and demanding high computational power which act as barriers to their integration into regular healthcare workflows. Research demonstrates that data-specific AI model selection becomes essential according to operational requirements of individual medical data collections and health facilities.

3. THEMATIC SECTIONS

3.1. Machine Learning in Structured Data

Machine learning algorithms demonstrate strong effectiveness in handling structured data consisting of laboratory examinations and electronic health records and demographic information and other table-based data sets. Random Forest (RF) and Gradient Boosting Machines (GBM) stand out because they process various data types effectively while addressing missing data while reducing overfitting through bagging and boosting techniques. For the improvement of prediction ML model results both selective feature methodology and data preparation techniques play important roles. Models can focus on diabetes risk factors by understanding that fasting glucose levels and body mass index (BMI) and age and insulin sensitivity stand as the most critical components for diagnosis. The accurate predictions from ML models result from running normalization along with missing value handling and categorical variable encoding as preprocessing steps. These steps enable smooth model operations. Structured info allows ML models to identify individuals who face high diabetes risk which enables prompt intervention along with personalized therapy care.

3.2. Deep Learning in Image and Signal Analysis

The DL algorithm has revolutionized the analysis of non-discrete data especially for medical imaging and time-series signal processing applications. The analysis of retinal fundus images for detecting diabetic retinopathy early requires extensive use of Convolutional Neural Networks (CNNs) since this condition develops in patients who do not receive proper diabetes treatment. Feature extraction capabilities of CNNs help identify complex medical patterns that include microaneurysms and hemorrhages as indications of retinal damage. The medical interpretation of continuous glucose monitoring (CGM) data proves successful through Recurrent Neural Networks (RNNs) and their refined versions such as Long Short-Term Memory (LSTM) networks. The processing capability of these models enables them to analyze time-based data along with extracting time-dependent glucose trends and patterns [32]. Unstructured data performs better under deep learning compared to conventional ML approaches because deep learning models excel at creating complex hierarchical patterns while managing complex data distribution patterns. Medical imaging and signal analysis benefit from DL model applications which result in accurate diagnoses as well as real-time disease tracking for personalized diabetes management.

3.3. Natural Language Processing for Risk Factor Extraction

Natural Language Processing (NLP) shows effectiveness in extracting risk factors from unstructured clinical notes together with physician reports as well as text-based medical information. The subtle information about patient history and symptoms together with lifestyle behavior and environmental influences appear in unstructured clinical text but not numerical data sets.

Figure 3: Benefit Of NLP In Healthcare

The software program NLP performs machine-based identification of diabetes risk factors within physician notes by detecting smoking practices and histories of TV use and sitting while tracking irregular eating patterns. Symptom descriptions in text such as frequent urination together with unexplained weight loss will be transformed by NLP into actionable diagnostic information resulting in earlier diagnoses. Two effective methods named Named Entity Recognition (NER) together with text categorization serve well to identify and label important clinical facts. NLP merges unstructured textual knowledge with structured data to boost AI-based diagnostic capability thus preventing important risk factors from getting omitted in diabetes prediction while improving management strategies.

Table 3: Research Study

References	Title	Topic Covered	Research Study
Lee, A. Y., Yanagihara, R. T., Lee, C. S., Blazes, M., Jung, H. C., Chee, Y. E., ... & Boyko, E. J. (2021) [33]	Head-to-head, multicentre, real-world validation study of seven automated AI-based diabetic retinopathy screening systems	Validation of AI systems for diabetic retinopathy screening	evaluated seven AI-based diabetic retinopathy screening methods using actual clinical data from several institutions.
Contreras, I., & Vehi, J. (2018) [34]	A overview of the research on artificial intelligence for diabetes management and decision assistance	AI applications in diabetes management	examined how AI is used to treat diabetes, with a focus on clinical applications and decision-support systems.
Wong, T. Y., & Bressler, N. M. (2016) [35]	Deep learning technology combined with artificial intelligence investigates diabetic retinopathy screening.	Deep learning for diabetic retinopathy	investigated the clinical implications of deep learning in diabetic retinopathy screening.
Rajalakshmi, R., Subashini, R., Anjana, R. M., & Mohan, V. (2018) [36]	Artificial intelligence-based automated identification of diabetic retinopathy in fundus photos taken with smartphones	AI-based smartphone detection	examined the use of AI to fundus imaging on smartphones for the detection of diabetic retinopathy.
Fogel, A. L., & Kvedar, J. C. (2018) [37]	Digital medicine is powered by artificial intelligence.	AI in digital medicine	emphasised how AI is revolutionising digital medicine and how it can lead to better health results.
Keel, S., Lee, P. Y., Scheetz, J., Li, Z., Kotowicz, M. A.,	A pilot study examining the viability and patient acceptability of a new AI-based diabetic retinopathy	Feasibility of AI-based diabetic	assessed whether an AI-driven screening paradigm in endocrinology clinics is

MacIsaac, R. J., & He, M. (2018) [38]	screening model at endocrinology outpatient services	retinopathy screening	feasible and acceptable to patients.
Jiang, F., Jiang, Y., Zhi, H., Dong, Y., Li, H., Ma, S., ... & Wang, Y. (2017) [39]	Healthcare AI: history, current state, and prospects	Overview of AI in healthcare	gave a thorough rundown of AI's uses in healthcare, including the diagnosis and treatment of diabetes.
Miller, D. D., & Brown, E. W. (2018) [40]	Artificial intelligence in medical practice: the question to the answer?	Ethical concerns in AI healthcare	discussed the practical, ethical, and legal issues surrounding the use of AI in medicine.

4. DISCUSSION

AI technology enhances the assessment of diabetes before early stages become noticeable especially when targeting high-risk populations. AI systems achieve better patient evaluation by joining various types of healthcare data (EHRs and sensor data and images). The general use of the models remains limited due to dataset biases coupled with non-standardization practices. Social and ethical issues regarding transparency as well as data privacy and algorithmic fairness need immediate resolution.

4.1. Interpret and Analyze the Findings

Artificial Intelligence technologies including Random Forest (RF) and Support Vector Machines (SVM) and Convolutional Neural Networks (CNN) demonstrate superior performance to traditional statistical models by processing large statistical datasets for prediction purposes. A combination of heterogeneous data forms including electronic health records (EHRs), continuous glucose monitoring (CGM) signals and retinal fundus images allows AI to conduct a broader medical assessment of patients. The pattern detection abilities of AI systems remain strong for processing complex datasets although the performance of these models declines when using biased training datasets in addition to the limitations it faces while being applied to diverse populations. Generalizability of models depends on obtaining representative and inclusive datasets which would improve their performance ability.

4.2. Discuss Implications and Significance

Healthcare experiences revolutionary changes because of the implementation of AI technology for diabetes diagnosis. AI enables healthcare staff to take early action against disease complications through its exact diagnostic predictions which help prevent neuropathy and cardiovascular disease and kidney failure. Deficits in healthcare delivery access get filled by AI through diagnostic systems that operate through telemedicine and point-of-care diagnostics especially serving populations who live in rural areas and areas with limited access to care. The efficient allocation of resources through AI helps healthcare facilities direct their screenings toward specific at-risk populations for prevention campaigns. The ethical barriers involving transparency as well as data privacy and algorithmic fairness need resolution to establish trust between healthcare professionals and their patients. The deployment of explainable AI systems improves model output understanding thus decreasing central issues related to the "black-box" nature of certain algorithms.

4.3. Highlight Gaps and Suggest Future Research Directions

- Standardized Datasets present the main constraint for AI model reliability and comparability because they have no standardized evaluation procedures and datasets. Universal criteria need to be developed for broad adoption.
- The requirement for high-quality data in AI systems creates challenges for their expansion into environments that have restricted resources. The development of adaptable AI systems for working with meager and sparse datasets needs future investigation.
- AI models usually fail to function properly after being exposed to datasets that contain noise or data imbalance. Specialized algorithms need to be developed for controlling the diversity that exists in real-world data.
- Organizations should resolve privacy and fairness issues as well as biases which affect ethical aspects of AI systems. Fair healthcare results can only be achieved when designs follow ethical principles with transparency in their operations.
- The effective and responsible use of AI depends on joint efforts between data scientists and doctors who work alongside ethicists in order to combine their academic perspectives.
- AI prediction ability and personalization will become more precise and fair through the integration of genetic along with behavioural and social health data.

5. CONCLUSION

Artificial Intelligence (AI) operates as a transformative technology for early diabetes diagnosis by establishing its superior precision combined with extreme prediction capabilities. The analysis of complex datasets by machine learning approaches combined with deep learning approaches leads to accurate high-risk subject identification which enables prompt preventive measures. Modern innovations can greatly decrease the diabetes impact by stopping complications from happening and improving patient health along with optimizing healthcare funding distribution. AI implementation within clinical settings remains at an early developmental stage because several obstacles need prompt resolution. Data quality together with model interpretability and regulatory compliance act as major barriers which prevent the scalability of the system. Well-quality datasets requiring representative samples demonstrate the need for improved inclusivity during data collection efforts especially with low-resource populations who are diverse. The unidentified characteristics of some AI models cause concerns regarding their clinical adoption along with their reliability.

5.1. Recommendations Of the Study

- XAI systems must be developed for ensuring transparency along with interpretability and building trust during clinical decision-making processes.

- The overall quality and multicultural diversity of training data needs to be improved through harmonization including the integration of minority population data sets without any built-in data biases.
- The establishment of regulatory systems should provide proper guidelines for ethical AI deployment together with standards regarding patient consent and data privacy protections for algorithmic fairness.
- Tool developers should provide cost-efficient diagnostic AI models that extend medical testing services through distant territories which serve underserved communities.
- The development of clinically useful ethical AI solutions needs healthcare experts to work with data experts and policy makers in cross-disciplinary teams.
- Healthcare teams must use real clinical data to assess and update AI models on a continuous basis to keep them effective for dynamic healthcare settings.

REFERENCES

1. Nomura, A., Noguchi, M., Kometani, M., Furukawa, K., & Yoneda, T. (2021). Artificial intelligence in current diabetes management and prediction. *Current Diabetes Reports*, *21*(12), 61.
2. Sheng, B., Chen, X., Li, T., Ma, T., Yang, Y., Bi, L., & Zhang, X. (2022). An overview of artificial intelligence in diabetic retinopathy and other ocular diseases. *Frontiers in Public Health*, *10*, 971943.
3. Huang, X., Wang, H., She, C., Feng, J., Liu, X., Hu, X., ... & Tao, Y. (2022). Artificial intelligence promotes the diagnosis and screening of diabetic retinopathy. *Frontiers in Endocrinology*, *13*, 946915.
4. Grauslund, J. (2022). Diabetic retinopathy screening in the emerging era of artificial intelligence. *Diabetologia*, *65*(9), 1415-1423.
5. Yin, J., Ngiam, K. Y., & Teo, H. H. (2021). Role of artificial intelligence applications in real-life clinical practice: systematic review. *Journal of medical Internet research*, *23*(4), e25759.
6. Kaplan, A., Cao, H., FitzGerald, J. M., Iannotti, N., Yang, E., Kocks, J. W., ... &Mastoridis, P. (2021). Artificial intelligence/machine learning in respiratory medicine and potential role in asthma and COPD diagnosis. *The Journal of Allergy and Clinical Immunology: In Practice*, *9*(6), 2255-2261.
7. Guan, Z., Li, H., Liu, R., Cai, C., Liu, Y., Li, J., ... & Sheng, B. (2023). Artificial intelligence in diabetes management: advancements, opportunities, and challenges. *Cell Reports Medicine*, *4*(10).
8. Kothinti, R. R. (2024). Artificial Intelligence in Disease Prediction: Transforming Early Diagnosis and Preventive Healthcare.
9. Rashid, J., Batool, S., Kim, J., Wasif Nisar, M., Hussain, A., Juneja, S., & Kushwaha, R. (2022). An augmented artificial intelligence approach for chronic diseases prediction. *Frontiers in Public Health*, *10*, 860396.

10. Abràmoff, M. D., Roehrenbeck, C., Trujillo, S., Goldstein, J., Graves, A. S., Repka, M. X., & Silva III, E. Z. (2022). A reimbursement framework for artificial intelligence in healthcare. *NPJ digital medicine*, *5*(1), 72.
11. Li, S., Zhao, R., & Zou, H. (2022). Artificial intelligence for diabetic retinopathy. *Chinese medical journal*, *135*(03), 253-260.
12. Abdullah, Y. I., Schuman, J. S., Shabsigh, R., Caplan, A., & Al-Aswad, L. A. (2021). Ethics of artificial intelligence in medicine and ophthalmology. *The Asia-Pacific Journal of Ophthalmology*, *10*(3), 289-298.
13. Parikh, R. B., &Helmchen, L. A. (2022). Paying for artificial intelligence in medicine. *NPJ digital medicine*, *5*(1), 63.
14. Kumar, Y., Koul, A., Singla, R., & Ijaz, M. F. (2023). Artificial intelligence in disease diagnosis: a systematic literature review, synthesizing framework and future research agenda. *Journal of ambient intelligence and humanized computing*, *14*(7), 8459-8486.
15. Kenner, B., Chari, S. T., Kelsen, D., Klimstra, D. S., Pandol, S. J., Rosenthal, M., ... & Wolpin, B. (2021). Artificial intelligence and early detection of pancreatic cancer: 2020 summative review. *Pancreas*, *50*(3), 251-279.
16. Manickam, P., Mariappan, S. A., Murugesan, S. M., Hansda, S., Kaushik, A., Shinde, R., &Thipperudraswamy, S. P. (2022). Artificial intelligence (AI) and internet of medical things (IoMT) assisted biomedical systems for intelligent healthcare. *Biosensors*, *12*(8), 562.
17. Ipp, E., Liljenquist, D., Bode, B., Shah, V. N., Silverstein, S., Regillo, C. D., ... &EyeArt Study Group. (2021). Pivotal evaluation of an artificial intelligence system for autonomous detection of referrable and vision-threatening diabetic retinopathy. *JAMA network open*, *4*(11), e2134254-e2134254.
18. Kanagasingam, Y., Xiao, D., Vignarajan, J., Preetham, A., Tay-Kearney, M. L., & Mehrotra, A. (2018). Evaluation of artificial intelligence–based grading of diabetic retinopathy in primary care. *JAMA network open*, *1*(5), e182665-e182665.
19. Beam, A. L., &Kohane, I. S. (2016). Translating artificial intelligence into clinical care. *Jama*, *316*(22), 2368-2369.
20. Stead, W. W. (2018). Clinical implications and challenges of artificial intelligence and deep learning. *Jama*, *320*(11), 1107-1108.
21. Takahashi, H., Tampo, H., Arai, Y., Inoue, Y., & Kawashima, H. (2017). Applying artificial intelligence to disease staging: Deep learning for improved staging of diabetic retinopathy. *PloS one*, *12*(6), e0179790.
22. El_Jerjawi, N. S., & Abu-Naser, S. S. (2018). Diabetes prediction using artificial neural network.
23. Benke, K., & Benke, G. (2018). Artificial intelligence and big data in public health. *International journal of environmental research and public health*, *15*(12), 2796.

24. Alagappan, M., Brown, J. R. G., Mori, Y., & Berzin, T. M. (2018). Artificial intelligence in gastrointestinal endoscopy: The future is almost here. *World journal of gastrointestinal endoscopy*, *10*(10), 239.
25. Yu, K. H., Beam, A. L., &Kohane, I. S. (2018). Artificial intelligence in healthcare. *Nature biomedical engineering*, *2*(10), 719-731.
26. López, B., Torrent-Fontbona, F., Viñas, R., & Fernández-Real, J. M. (2018). Single Nucleotide Polymorphism relevance learning with Random Forests for Type 2 diabetes risk prediction. *Artificial intelligence in medicine*, *85*, 43-49.
27. Deepa, S. N., & Devi, B. A. (2011). A survey on artificial intelligence approaches for medical image classification. *Indian Journal of Science and Technology*, *4*(11), 1583-1595.
28. Barakat, N., Bradley, A. P., & Barakat, M. N. H. (2010). Intelligible support vector machines for diagnosis of diabetes mellitus. *IEEE transactions on information technology in biomedicine*, *14*(4), 1114-1120.
29. Gargeya, R., & Leng, T. (2017). Automated identification of diabetic retinopathy using deep learning. *Ophthalmology*, *124*(7), 962-969.
30. Panch, T., Szolovits, P., & Atun, R. (2018). Artificial intelligence, machine learning and health systems. *Journal of global health*, *8*(2), 020303.
31. Munirathnam, R., &Kanchetti, D. (2024). Artificial Intelligence (AI)-Powered Predictive Models in Chronic Disease Management: A Data-Driven Approach. *Journal ID*, *9471*, 1297.
32. Gupta, P. P. (2023). Applications of AI-driven data analytics for early diagnosis in complex medical conditions. *INTERNATIONAL JOURNAL OF ENGINEERING APPLICATIONS OF ARTIFICIAL INTELLIGENCE (IJEAAI)*, *1*(2), 1-9.
33. Lee, A. Y., Yanagihara, R. T., Lee, C. S., Blazes, M., Jung, H. C., Chee, Y. E., ... & Boyko, E. J. (2021). Multicenter, head-to-head, real-world validation study of seven automated artificial intelligence diabetic retinopathy screening systems. *Diabetes care*, *44*(5), 1168-1175.
34. Contreras, I., & Vehi, J. (2018). Artificial intelligence for diabetes management and decision support: literature review. *Journal of medical Internet research*, *20*(5), e10775.
35. Wong, T. Y., & Bressler, N. M. (2016). Artificial intelligence with deep learning technology looks into diabetic retinopathy screening. *Jama*, *316*(22), 2366-2367.
36. Rajalakshmi, R., Subashini, R., Anjana, R. M., & Mohan, V. (2018). Automated diabetic retinopathy detection in smartphone-based fundus photography using artificial intelligence. *Eye*, *32*(6), 1138-1144.
37. Fogel, A. L., & Kvedar, J. C. (2018). Artificial intelligence powers digital medicine. *NPJ digital medicine*, *1*(1), 5.
38. Keel, S., Lee, P. Y., Scheetz, J., Li, Z., Kotowicz, M. A., MacIsaac, R. J., &

He, M. (2018). Feasibility and patient acceptability of a novel artificial intelligence-based screening model for diabetic retinopathy at endocrinology outpatient services: a pilot study. *Scientific reports*, *8*(1), 4330.

39. Jiang, F., Jiang, Y., Zhi, H., Dong, Y., Li, H., Ma, S., ... & Wang, Y. (2017). Artificial intelligence in healthcare: past, present and future. *Stroke and vascular neurology*, *2*(4).
40. Miller, D. D., & Brown, E. W. (2018). Artificial intelligence in medical practice: the question to the answer? *The American journal of medicine*, *131*(2), 129-133.